Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Kiora Pharmaceuticals (KPRX)
NASDAQ:KPRX
RESEARCH TOOLSreports
Kiora Pharmaceuticals (KPRX) Stock Price & Analysis
406 Followers
KPRX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$3.60 - $8.98
Previous Close$4.29
Volume24.06K
Average Volume (3M)33.66K
Market Cap
$12.74M
Enterprise Value$10.35M
Total Cash (Recent Filing)$2.50M
Total Debt (Recent Filing)$106.89K
Price to Earnings (P/E)―
Beta-0.21
Next Earnings
Aug 08, 2024EPS Estimate
-$0.81Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-14.31
Shares Outstanding2,970,568
10 Day Avg. Volume85,087
30 Day Avg. Volume33,660
Standard Deviation0.27
R-Squared0.00187
Alpha-0.05
Financial Highlights & Ratios
Price to Book (P/B)-15.43
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-2.38
Forecast
1Y Price Target
$2.50Price Target Upside-42.85% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Kiora Pharmaceuticals News
PremiumCompany Announcements
Kiora Pharmaceuticals Announces Board Appointment, Regains Nasdaq Compliance
PremiumCompany Announcements
Kiora Pharmaceuticals Unveils Updated Investor Presentation
PremiumCompany Announcements
Kiora Pharmaceuticals Announces Securities Purchase Agreements
PremiumCompany Announcements
Kiora Pharmaceuticals Reveals TOI Agreement and PresentationBulls Say, Bears Say
Bulls Say
Clinical DevelopmentKIO-301 is set to enter a Phase 2 trial for retinitis pigmentosa, highlighting the progress in its clinical development.
Financial StabilityKiora has secured funding through 2026, which includes a substantial upfront from partnerships and private placements, providing financial stability.
Strategic PartnershipsKiora Pharmaceuticals entered into a strategic development and commercialization agreement with Théa Open Innovation, which will fund the remaining clinical development of KIO-301 across multiple indications.
Bears Say
Clinical TrialsPotential failure of KIO-301 in clinical trials could impact the stock negatively.
Financial PerformanceNet loss totaled $13.0M, indicating financial struggles.
Regulatory ApprovalFailure to secure regulatory approval for KIO-301 poses a significant risk.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
KPRX FAQ
What was Kiora Pharmaceuticals’s price range in the past 12 months?
Kiora Pharmaceuticals lowest stock price was $3.60 and its highest was $8.98 in the past 12 months.
What is Kiora Pharmaceuticals’s market cap?
Currently, no data Available
When is Kiora Pharmaceuticals’s upcoming earnings report date?
Kiora Pharmaceuticals’s upcoming earnings report date is Aug 08, 2024 which is in 21 days.
How were Kiora Pharmaceuticals’s earnings last quarter?
Kiora Pharmaceuticals released its earnings results on May 10, 2024. The company reported $3.42 earnings per share for the quarter, beating the consensus estimate of $2.475 by $0.945.
Is Kiora Pharmaceuticals overvalued?
According to Wall Street analysts Kiora Pharmaceuticals’s price is currently Overvalued.
Does Kiora Pharmaceuticals pay dividends?
Kiora Pharmaceuticals does not currently pay dividends.
What is Kiora Pharmaceuticals’s EPS estimate?
Kiora Pharmaceuticals’s EPS estimate is -$0.81.
How many shares outstanding does Kiora Pharmaceuticals have?
Kiora Pharmaceuticals has 2,970,568 shares outstanding.
What happened to Kiora Pharmaceuticals’s price movement after its last earnings report?
Kiora Pharmaceuticals reported an EPS of $3.42 in its last earnings report, beating expectations of $2.475. Following the earnings report the stock price went up 0.229%.
Which hedge fund is a major shareholder of Kiora Pharmaceuticals?
Currently, no hedge funds are holding shares in KPRX
---
Kiora Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$2.50 (-42.85% Downside)
$2.50 (-42.85% Downside)
Insider Transactions
Bought Shares
Worth $48.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 9.6%
Last 30 Days ▼ 9.6%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-24.93%
12-Months-Change
Fundamentals
Return on Equity
12.46%
Trailing 12-Months
Asset Growth
156.78%
Trailing 12-Months
Company Description
Kiora Pharmaceuticals
EyeGate Pharmaceuticals, Inc. is a clinical stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. Its pipeline includes EGP-437 and Ocular Bandage Gel. The company was founded in 1998 and is headquartered in Waltham, MA.
---
KPRX Stock 12 Month Forecast
Average Price Target
$2.50
▼(-42.85% Downside)
Technical Analysis
Best Analysts Covering KPRX
1 Year
1 Year Success Rate
0/14 ratings generated profit
1 Year Average Return
-64.87%
reiterated a buy rating 2 months ago
Copying Yi Chen's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -64.87% per trade.
---